



January 14, 2014

To whom it may concern:

Company name: Nichi-Iko Pharmaceutical Co., Ltd.
(Securities code: 4541 Tokyo Stock Exchange, First Section)
Representative: Yuichi Tamura
President and CEO
Contact: Noboru Inasaka
Managing Executive Officer and General
Manager of Management Division
(Tel: 076-432-2121)

**Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd.
Stock Acquisition Rights No. 5 by Existing Shareholders, etc.**

Nichi-Iko Pharmaceutical Co., Ltd. (the "Company") hereby announces that, regarding the Company's Stock Acquisition Rights No. 5 (the "Stock Acquisition Rights"), on January 14, 2014, Yuichi Tamura, the President and CEO of the Company and also the major shareholder of the Company, TAMURA Co., Ltd., the largest shareholder of the Company, and Taku Co., Ltd., the wholly owned subsidiary of TAMURA Co., Ltd., have reported that they have taken the procedures concerning the proposal of the request for exercise and the payment of the Exercise Price for all of the 5,474,099 Stock Acquisition Rights, which is the total of the Stock Acquisition Rights allotted to Yuichi Tamura and TAMURA Co., Ltd., in accordance with the policy stated in "6. Trends of Existing Shareholders, etc." in the "Notice Concerning the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution)" dated November 27, 2013. This notice relates to the commitment-type rights offering which was announced by the Company in such press release.

The Company also announces that The Hokuriku Bank, Ltd. has reported that it has exercised all of the Stock Acquisition Rights that were allotted to it, and that Sanofi K.K. has reported that it intends to exercise all of the Stock Acquisition Rights that were allotted to it.

Furthermore, all of the directors and executive officers of the Company have reported that they intend to exercise all of the Stock Acquisition Rights that were allotted to them.

The Company is not able to confirm the status of exercise of the Stock Acquisition Rights of the other shareholders as of January 14, 2014, and therefore, this notice is not an announcement of the status of exercise of the Stock Acquisition Rights or the total number of the Company's issued shares as of January 14, 2014.

E N D

Notice:

This document is a statement to be announced publicly with regard to the status of exercise of the Stock Acquisition Rights No. 5 by existing shareholders, etc. of the Company and has not been prepared for the purpose of soliciting investments. Please note that shareholders or investors should carefully read the securities registration statement (<http://disclosure.edinet-fsa.go.jp/>) filed on November 27, 2013, and to take responsibility for the exercise or trading of, or making other investment decisions with respect to the Stock Acquisition Rights.

This document is not intended as a solicitation for any offering or purchase of securities outside Japan. With respect to the issuance of the Stock Acquisition Rights, no registration under the securities laws or other laws and regulations of any jurisdictions outside Japan (including the U.S. Securities Act of 1933, as amended) has been made and no such registration is planned.